flotillin-2 与乳腺癌的进展和不良预后相关。
Flotillin-2 is associated with breast cancer progression and poor survival outcomes.
机构信息
State Key Laboratory of Oncology in South China, Guangzhou 510060, PR China.
出版信息
J Transl Med. 2013 Aug 15;11:190. doi: 10.1186/1479-5876-11-190.
BACKGROUND
Flotillin-2 (FLOT2) has been implicated in several signaling pathways in tumor cells. Our study aimed to investigate the expression pattern and clinicopathological significance of FLOT2 in patients with breast cancer.
METHODS
The expression level of FLOT2 in normal breast epithelial cells, breast cancer cell lines, and four breast cancer biopsies paired with adjacent noncancerous tissues were quantified using real-time RT-PCR and Western blotting. FLOT2 protein expression was analyzed in 171 archived paraffin-embedded breast cancer samples using immunohistochemistry (IHC). Statistical analyses were performed to evaluate the clinicopathological significance of FLOT2 expression.
RESULTS
FLOT2 was significantly upregulated in breast cancer cell lines and tissue samples compared with normal cells and adjacent noncancerous breast tissues, respectively. IHC analysis revealed high expression levels of FLOT2 in 82 of 171 (48.0%) breast cancer specimens. Statistical analysis revealed that FLOT2 expression was significantly correlated with clinical stage (P < 0.001), T classification (P < 0.001), M classification (P < 0.001), histological differentiation (P = 0.005) and ErbB2 expression (P = 0.003). Patients with higher levels of FLOT2 expression had a shorter overall survival duration than patients with lower FLOT2 expression levels. Multivariate analysis suggested that FLOT2 expression was an independent prognostic marker for survival in patients with breast cancer.
CONCLUSIONS
The current results demonstrated that high FLOT2 protein expression was associated with poor outcomes in patients with breast cancer. FLOT2 could be used as a prognostic biomarker for breast cancer progression.
背景
Flotillin-2（FLOT2）已被牵涉到肿瘤细胞中的几个信号通路中。我们的研究旨在调查 FLOT2 在乳腺癌患者中的表达模式和临床病理意义。
方法
使用实时 RT-PCR 和 Western blot 定量检测正常乳腺上皮细胞、乳腺癌细胞系和 4 对乳腺癌活检及其相邻非癌组织中 FLOT2 的表达水平。使用免疫组织化学（IHC）分析 171 例存档石蜡包埋乳腺癌样本中的 FLOT2 蛋白表达。进行统计分析以评估 FLOT2 表达的临床病理意义。
结果
与正常细胞和相邻非癌性乳腺组织相比，FLOT2 在乳腺癌细胞系和组织样本中均显著上调。IHC 分析显示，171 例乳腺癌标本中有 82 例（48.0%）FLOT2 表达水平较高。统计分析表明，FLOT2 表达与临床分期（P < 0.001）、T 分类（P < 0.001）、M 分类（P < 0.001）、组织学分化（P = 0.005）和 ErbB2 表达（P = 0.003）显著相关。FLOT2 表达水平较高的患者总生存时间短于 FLOT2 表达水平较低的患者。多变量分析表明，FLOT2 表达是乳腺癌患者生存的独立预后标志物。
结论
目前的结果表明，FLOT2 蛋白高表达与乳腺癌患者的不良预后相关。FLOT2 可作为乳腺癌进展的预后生物标志物。
Zotero 插件